Clinical trials in Lingen (Ems)

9 clinical trials in Lingen (Ems), Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Lingen (Ems) at a glance

clinical trials

Not yet recruiting0
Paediatric trials0
Research sites0

Quick filters

9 trials in Lingen (Ems)

Open in trial search

Type 2 diabetes mellitus+2

Recruiting

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Obesity+1

Recruiting

A study to evaluate the effectiveness and safety of eloralintide in adults with obesity or overweight without type 2 diabetes.

Investigational

A study to evaluate the effectiveness and safety of eloralintide in adults with obesity or overweight without type 2 diabetes.

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:LY3841136 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Actinic keratosis

Recruiting

Study on the Effectiveness of 5% Potassium Hydroxide Solution for Treating Mild to Moderate Actinic Keratosis in Adults

Investigational

Study on the Effectiveness of 5% Potassium Hydroxide Solution for Treating Mild to Moderate Actinic Keratosis in Adults

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Potassium hydroxide
Sponsor:INFECTOPHARM Arzneimittel und Consilium GmbH

Contact Research Centre

Chronic kidney disease

Not recruiting

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Obesity

Not recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational

Germany

Participants:18–64 years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Obesity

Not recruiting

Study Comparing Retatrutide and Tirzepatide for Weight Loss in Adults with Obesity

InvestigationalNo placebo

Study Comparing Retatrutide and Tirzepatide for Weight Loss in Adults with Obesity

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

Study Comparing Orforglipron and Dapagliflozin for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Metformin

Registered drugNo placebo

Study Comparing Orforglipron and Dapagliflozin for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Metformin

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dapagliflozin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Polycythaemia vera

Not recruiting

Study on Hydroxycarbamide Resistance in Patients with Polycythemia Vera Identified by AI Predictors

Registered drugNo placebo

Study on Hydroxycarbamide Resistance in Patients with Polycythemia Vera Identified by AI Predictors

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Hydroxycarbamide
Sponsor:Novartis Pharma GmbH

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 513 cities in Germany

Clinical research in Lingen (Ems)

What the registry says about research in the country

01 Hematology Research

Innovative clinical trials focusing on polycythemia vera treatment resistance patterns are being conducted using artificial intelligence-driven approaches. These studies aim to evaluate how patients respond to hydroxyurea therapy, particularly in cases where treatment resistance may develop.

Blood disorder management
Treatment resistance prediction
AI-assisted medical research

This prospective intervention study represents a significant advancement in personalizing treatment approaches for blood disorders through machine learning applications in clinical medicine.

Back to Germany All countries